Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | PTAFR | P25105 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | TUBB4A | P04350 | 4/20 | 0.40 |
| ▸ | TUBB | P07437 | 4/20 | 0.40 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.40 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.40 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.40 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.40 |
| ▸ | TUBB3 | Q13509 | 4/20 | 0.40 |
| ▸ | TUBB2A | Q13885 | 4/20 | 0.40 |
| ▸ | TUBB8 | Q3ZCM7 | 4/20 | 0.40 |
| ▸ | TUBA3E | Q6PEY2 | 4/20 | 0.40 |
| ▸ | TUBA1A | Q71U36 | 4/20 | 0.40 |
| ▸ | TUBA1C | Q9BQE3 | 4/20 | 0.40 |
| ▸ | TUBB6 | Q9BUF5 | 4/20 | 0.40 |
| ▸ | TUBB2B | Q9BVA1 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4438294 | 0.98 | MAPT (0.44) | MAPTTSHRPTAFRNPC1PTPN1 | |
| SCHEMBL4436046 | 0.75 | KDM4E (0.41) | MAPTTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL14008435 | 0.74 | KDM4E (0.58) | ACHETUBB4ATUBBTUBA3CTUBA1B | |
| Hydrochloric Acid SCHEMBL4438258 | 0.74 | POLB (0.43) | MAPTTUBB4ATUBBTUBA3CTUBA1B | |
| Hydrochloric Acid SCHEMBL4445449 | 0.73 | POLB (0.60) | ACHETUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL29267402 | 0.73 | PTAFR (0.62) | MAPTTSHRPTAFRNPC1PTPN1 | |
| SCHEMBL17931328 | 0.70 | GAA (0.36) | KMT2AALDH1A1KDM4E | |
| SCHEMBL20128521 | 0.70 | ALDH1A1 (0.43) | MAPTTSHRNPC1KMT2AMEN1 | |
| SCHEMBL9719080 | 0.70 | PTAFR (0.58) | MAPTTSHRPTAFRNPC1PTPN1 | |
| SCHEMBL9719087 | 0.70 | PTAFR (0.58) | MAPTTSHRPTAFRNPC1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125716-A2 | HYDROXYLAMINE COMPOUNDS AND METHODS OF THEIR USE | Othera Holding, Inc. (US) | 2009-12-02 | — | — | EP | claimed |
| US-20080280890-A1 | HYDROXYLAMINE COMPOUNDS AND METHODS OF THEIR USE | COLBY PHARMACEUTICAL COMPANY | 2008-11-13 | — | — | US | claimed |
| WO-2008103613-A2 | HYDROXYLAMINE COMPOUNDS AND METHODS OF THEIR USE | OTHERA HOLDING, INC. (US) | 2008-08-28 | — | — | WO | claimed |
| CN-103497148-A | Hydroxylamine compounds and methods of their use | OTHERA HOLDING INC | 2014-01-08 | — | — | CN | disclosed |
| EP-2620429-A1 | Hydroxylamine compounds and methods of their use | Colby Pharmaceutical Company (US) | 2013-07-31 | — | — | EP | disclosed |
| CN-101687786-B | Hydroxylamine compounds and methods of use thereof | OTHERA HOLDING INC | 2013-05-22 | — | — | CN | disclosed |
| EP-2125716-A2 | HYDROXYLAMINE COMPOUNDS AND METHODS OF THEIR USE | Othera Holding, Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| EP-2120942-A2 | DRUG RESISTANCE REVERSAL IN NEOPLASTIC DISEASE | Othera Holding, Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080280890-A1 | HYDROXYLAMINE COMPOUNDS AND METHODS OF THEIR USE | COLBY PHARMACEUTICAL COMPANY | 2008-11-13 | — | — | US | disclosed |
| WO-2008103613-A2 | HYDROXYLAMINE COMPOUNDS AND METHODS OF THEIR USE | OTHERA HOLDING, INC. (US) | 2008-08-28 | — | — | WO | disclosed |
| US-20080200405-A1 | Drug Resistance Reversal In Neoplastic Disease | COLBY PHARMACEUTICAL COMPANY | 2008-08-21 | — | — | US | disclosed |
| WO-2008101195-A2 | DRUG RESISTANCE REVERSAL IN NEOPLASTIC DISEASE | OTHERA HOLDING, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280890-A1 | HYDROXYLAMINE COMPOUNDS AND METHODS OF THEIR USE | HDGF, HMOX1, HMOX2 | MAPT 2334/4885TSHR 1831/4885PTAFR 176/4885 |
| US-20080200405-A1 | Drug Resistance Reversal In Neoplastic Disease | VHL, ABCC1, SLC11A2 | MAPT 2753/4885TSHR 2111/4885PTAFR 2435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.